{
    "Symbol": "INSM",
    "AssetType": "Common Stock",
    "Name": "Insmed Inc",
    "Description": "Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.",
    "CIK": "1104506",
    "Exchange": "NASDAQ",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "PHARMACEUTICAL PREPARATIONS",
    "Address": "700 US HIGHWAY 202/206, BRIDGEWATER, NJ, US",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2024-03-31",
    "MarketCapitalization": "11713576000",
    "EBITDA": "-671894976",
    "PERatio": "None",
    "PEGRatio": "0",
    "BookValue": "-3.129",
    "DividendPerShare": "None",
    "DividendYield": "None",
    "EPS": "-5.23",
    "RevenuePerShareTTM": "2.199",
    "ProfitMargin": "-2.367",
    "OperatingMarginTTM": "-2.085",
    "ReturnOnAssetsTTM": "-0.318",
    "ReturnOnEquityTTM": "-14.53",
    "RevenueTTM": "315494000",
    "GrossProfitTTM": "190232000",
    "DilutedEPSTTM": "-5.23",
    "QuarterlyEarningsGrowthYOY": "0",
    "QuarterlyRevenueGrowthYOY": "0.158",
    "AnalystTargetPrice": "84.53",
    "AnalystRatingStrongBuy": "5",
    "AnalystRatingBuy": "12",
    "AnalystRatingHold": "0",
    "AnalystRatingSell": "0",
    "AnalystRatingStrongSell": "0",
    "TrailingPE": "-",
    "ForwardPE": "-",
    "PriceToSalesRatioTTM": "37.13",
    "PriceToBookRatio": "30.41",
    "EVToRevenue": "40.9",
    "EVToEBITDA": "-6.05",
    "Beta": "1.16",
    "52WeekHigh": "78.87",
    "52WeekLow": "21.21",
    "50DayMovingAverage": "63.78",
    "200DayMovingAverage": "36.1",
    "SharesOutstanding": "163119000",
    "DividendDate": "None",
    "ExDividendDate": "None"
}